Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...

Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...

A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating ...

About 1 million people are living with multiple sclerosis in the U.S., and about 10% of those have PPMS, making it the least common form of the disease.

TG Therapeutics is gearing up for a new clinical trial, dubbed ULTIMATE, to test Briumvi in children and adolescents with ...

Cerebrospinal fluid (CSF)-based molecular tests can reliably distinguish multiple sclerosis (MS) from other neurological ...

BERLIN, Feb 7 (Reuters) - Swiss pharmaceutical company Roche said on Saturday its experimental multiple sclerosis drug ...

People typically develop multiple sclerosis between ages 20 and 40, but late-onset MS affects those 50 years and older. Your doctor can best diagnose and advise on possible treatments, such as ...

Could plastic byproducts and forever chemicals found in drinking water cause your body to attack your own nervous system? New ...

Researchers at UC San Francisco have uncovered a new clue to how Epstein-Barr virus (EBV) could contribute to multiple ...

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.

Multiple sclerosis can affect many areas of your daily life, including dental care. Symptoms of multiple sclerosis and the medications you take for these symptoms can lead to an increased need for ...